[
  {
    "ts": null,
    "headline": "From Stagnation To Surge: Gilead Sciences Is Entering Its Next Growth Wave",
    "summary": "Gilead Sciences is accelerating its growth rate and Yeztugo might be another major blockbuster. GILD stock is still trading below its intrinsic value. See more.",
    "url": "https://finnhub.io/api/news?id=11187a32f1920d307ace9cd143a14876dd2476d1272421040164f807b22d119e",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755730133,
      "headline": "From Stagnation To Surge: Gilead Sciences Is Entering Its Next Growth Wave",
      "id": 136449308,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2162514544/image_2162514544.jpg?io=getty-c-w1536",
      "related": "GILD",
      "source": "SeekingAlpha",
      "summary": "Gilead Sciences is accelerating its growth rate and Yeztugo might be another major blockbuster. GILD stock is still trading below its intrinsic value. See more.",
      "url": "https://finnhub.io/api/news?id=11187a32f1920d307ace9cd143a14876dd2476d1272421040164f807b22d119e"
    }
  },
  {
    "ts": null,
    "headline": "Exclusive-CVS holds off adding Gilead’s new HIV prevention shot to drug coverage lists",
    "summary": "(Reuters) -CVS Health, which runs the largest U.S. pharmacy benefit manager, will not add Gilead Sciences' new HIV prevention drug to its commercial plans for now, a spokesperson told Reuters, despite the medicine's proven effectiveness.  CVS based the decision on clinical, financial, and regulatory factors, spokesperson David Whitrap said in an email.  It also will not cover Yeztugo under its Affordable Care Act formularies, since its ACA preventive program follows recommendations and mandates from the U.S. Department of Health and Human Services (HHS), Whitrap said.",
    "url": "https://finnhub.io/api/news?id=1dbe2186d8eaa695508cd6264027cff5f43b332f0c5a2c768a38550418846fa5",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755722471,
      "headline": "Exclusive-CVS holds off adding Gilead’s new HIV prevention shot to drug coverage lists",
      "id": 136450498,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "(Reuters) -CVS Health, which runs the largest U.S. pharmacy benefit manager, will not add Gilead Sciences' new HIV prevention drug to its commercial plans for now, a spokesperson told Reuters, despite the medicine's proven effectiveness.  CVS based the decision on clinical, financial, and regulatory factors, spokesperson David Whitrap said in an email.  It also will not cover Yeztugo under its Affordable Care Act formularies, since its ACA preventive program follows recommendations and mandates from the U.S. Department of Health and Human Services (HHS), Whitrap said.",
      "url": "https://finnhub.io/api/news?id=1dbe2186d8eaa695508cd6264027cff5f43b332f0c5a2c768a38550418846fa5"
    }
  },
  {
    "ts": null,
    "headline": "Gilead Sciences to Present at Upcoming Investor Conferences",
    "summary": "FOSTER CITY, Calif., August 20, 2025--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its executives will be speaking at the following investor conferences:",
    "url": "https://finnhub.io/api/news?id=d316297275401d397469b0cb984d66cbfceb69b084ca4c8bf029c7f1b7465e1e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755720300,
      "headline": "Gilead Sciences to Present at Upcoming Investor Conferences",
      "id": 136450499,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "FOSTER CITY, Calif., August 20, 2025--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its executives will be speaking at the following investor conferences:",
      "url": "https://finnhub.io/api/news?id=d316297275401d397469b0cb984d66cbfceb69b084ca4c8bf029c7f1b7465e1e"
    }
  },
  {
    "ts": null,
    "headline": "BTS and clients recognized with 59 Brandon Hall Group Excellence Awards in 2025",
    "summary": "SAN FRANCISCO, August 20, 2025--BTS has earned 59 Brandon Hall Group Excellence Awards in 2025 alongside its clients.",
    "url": "https://finnhub.io/api/news?id=17450636819ecb38592918b7aa4e32c5f337e68296987a118920532f87af5d68",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755691200,
      "headline": "BTS and clients recognized with 59 Brandon Hall Group Excellence Awards in 2025",
      "id": 136437525,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "SAN FRANCISCO, August 20, 2025--BTS has earned 59 Brandon Hall Group Excellence Awards in 2025 alongside its clients.",
      "url": "https://finnhub.io/api/news?id=17450636819ecb38592918b7aa4e32c5f337e68296987a118920532f87af5d68"
    }
  }
]